Thrombopoietin mimetics

A compound represented by the following Formula:

• wherein:
• R, R1, R2 and R3 are each independently selected from hydrogen, C1-6alkyl, —(CH2)pOR4, —C(O)OR4, formyl, nitro, cyano, halogen, aryl, aryl substituted by one or more substituents selected from the group consisting of:
• —CO2R22, aryl, —C(O)NHS(O)2R20, —NHS(O)2R20, hydroxyalkyl, alkoxy, —C(O)NR21R22, acyloxy, alkyl, amino, N-acylamino, hydroxy, —(CH2)gC(O)OR8, —S(O)nR8, nitro, tetrazole, cyano, halogen, trifluoromethyl, protected —OH and a heterocyclic methylene substituent as represented by Formula (III),
• where g is 0-6;
• R8 is hydrogen or alkyl;
• R20 is selected from hydrogen, C1-C4alkyl, aryl and trifluoromethyl;
• R21 and R22 are independently selected from hydrogen, C1-C4alkyl, aryl and trifluoromethyl;
• V, W, X and Z are each independently selected from O, S, and NR16, where R16 is selected from:
• hydrogen, alkyl, cycloalkyl, C1-C12aryl, substituted alkyl, substituted cycloalkyl and substituted C1-C12aryl;
• and n is 0-2.
• substituted alkyl, —S(O)nR4, cycloalkyl, —NR5R6, protected —OH, —CONR5R6, phosphonic acid, sulfonic acid, phosphinic acid, —SO2NR5R6, and a heterocyclic methylene substituent as represented by Formula (III),
• where
• p is 0-6,
• n is 0-2,
• V, W, X and Z are each independently selected from O, S, and NR16, where R16 is selected from:
• hydrogen, alkyl, cycloalkyl, C1-C12aryl, substituted alkyl, substituted cycloalkyl and substituted C1-C12aryl,
• R4 is hydrogen, alkyl, cycloalkyl, C1-C12aryl, substituted alkyl, substituted cycloalkyl and substituted C1-C12aryl, and
• R5 and R6 are each independently selected from hydrogen, alkyl, substituted alkyl, C3-6cycloalkyl, and aryl,
• or R5 and R6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen;
• R15 is selected from the group consisting of alkyl, C1-C12aryl, alkoxy, substituted alkyl, substituted C1-C12aryl and halogen;
• m is 0-6;
• and
• Y is selected from alkyl, substituted alkyl and a cyclic or polycyclic aromatic ring containing from 3 to 14 carbon atoms and optionally containing from one to three heteroatoms, provided that when the number of carbon atoms is 3, the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4, the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of:
• alkyl, substituted alkyl, C1-C12aryl, substituted cycloalkyl, substituted C1-C12aryl, hydroxy, aryloxy, alkoxy, cycloalkyl, nitro, cyano, halogen and protected —OH;
• or a pharmaceutically acceptable salt thereof;
• provided that at least one of R, R1, R2 and R3 is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III).